Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07468526 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

An Ultra-short Course of Primaquine for the Radical Cure of Vivax Malaria

Study acronym: PRIMUS
StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Current treatment regimens to prevent relapsing malaria are too long. A shorter higher dose treatment could improve treatment outcomes, but this needs to be balanced against increased risk of side effects. Recent data from a trial in children in Papua New Guinea (PNG) suggests a shortened treatment of 3 days is safe and effective. Our multicentre trial will assess the safety and efficacy of an ultra-short primaquine course. This trial is expected to directly influence global treatment policies.
Trial Details
NCT Number NCT07468526
Lead Sponsor Menzies School of Health Research
Collaborators: Curtin University, University of Melbourne, Papua New Guinea Institute of Medical Research, Arba Minch University, Jimma University, Universitas Sumatera Utara, Aga Khan University, PathWest Laboratory Medicine WA
Conditions
(from sponsor)		 Malaria
Related terms Malaria
Enrollment 1,019 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov